Please login to the form below

Not currently logged in
Email:
Password:

ZS Pharma

This page shows the latest ZS Pharma news and features for those working in and with pharma, biotech and healthcare.

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

AZ acquired Lokelma ( sodium zirconium cyclosilicate) via a $2.7bn acquisition of ZS Pharma three years ago, but suffered serious setbacks in its approval thanks to manufacturing compliance issues.

Latest news

  • Real-world data finds patients feel better on Entresto, says Novartis Real-world data finds patients feel better on Entresto, says Novartis

    Lokelma (sodium zirconium cyclosilicate or ZS-9) and Vifor Pharma’s Veltassa (patiromer) which “will be a particularly valuable addition to the clinic if efficacy can be confirmed in clinical trials”.

  • AZ gets US approval for Veltassa rival Lokelma AZ gets US approval for Veltassa rival Lokelma

    AstraZeneca has picked up FDA approval for its hyperkalaemia treatment Lokelma, allowing it to compete head-to-head with rival Vifor Pharma on both sides of the Atlantic. ... AZ acquired Lokelma via the $2.7bn acquisition of ZS Pharma three years ago

  • AZ finally gets EU nod for Veltassa rival Lokelma AZ finally gets EU nod for Veltassa rival Lokelma

    challenge Vifor Pharma’s Veltassa (patiromer) which was approved in the EU last year and has been sold in the US since 2015. ... The European approval finally puts AZ on course to make a return from its $2.7bn purchase of Lokelma’s originator ZS

  • FDA turns down AZ's ZS-9 once again on manufacturing issues FDA turns down AZ's ZS-9 once again on manufacturing issues

    AZ and ZS Pharma are committed to working with the FDA to resolve the remaining matters under review as soon as possible," it said in a statement. ... When AZ bought ZS Pharma it described ZS-9 as a "best in class" potassium-binder with sales potential

  • AZ nears EU approval for hyperkalaemia drug Lokelma AZ nears EU approval for hyperkalaemia drug Lokelma

    The drug was originally developed by ZS Pharma, which described Lokelma as a “potential best-in-class treatment” and tipped it as a potential blockbuster. ... Speaking at the time of ZS Pharma's acquisition, AstraZeneca's chief executive Pascal

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    The CRL refers to a manufacturing issue. ZS-9 was acquired when the company purchased ZS Pharma for $2.7bn. ... Reported in DW Issue 65 [November 2015] AstraZeneca had out bid Actelion who were also in the running to buy ZS Pharma at that time.

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    metabolism. Meanwhile, further evidence for an uptick in pharma industry interest in HF is witnessed by recent licensing/acquisition deals. ... of ZS Pharma and ZS-9, a drug being developed to treat elevated potassium levels in HF patients.

  • Deal Watch November 2015 Deal Watch November 2015

    Also doing the double and buying and selling AstraZeneca continued its busy deal profile with the acquisition of ZS Pharma and the divestment in the US of Entocort. ... ZS Pharma. AstraZeneca. Acquisition - company. Lead product ZS-9, potassium-binding

  • Pharma deals in September 2015 Pharma deals in September 2015

    Transformational deals. The two largest deals announced this month were Cinven's sale of Amdipharm Mercury (AMCo) to Concordia Healthcare and Actelion's move to acquire ZS Pharma, at $3.5bn ... 3, 500. ZS Pharma. Actelion. ZS-9 to treat hyperkalemia

  • Sales reps struggle to access doctors Sales reps struggle to access doctors

    Relationships reached by sales force size.  . Source: ZS Associates  . Making proper use of that well-worn buzz word 'customer-centric' marketing will be key - along with careful channel choice – if pharma ... companies are to gain physician attention

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics